Alterations in the Anandamide Metabolism in the Development of Neuropathic Pain

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Malek, Natalia ^a   Kucharczyk, Mateusz ^a   Starowicz, Katarzyna ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ANANDAMIDE; ENDOCANNABINOID; MESSENGER RNA; AMIDE; ARACHIDONIC ACID DERIVATIVE; CANNABINOID 2 RECEPTOR; PHOSPHATIDYLETHANOLAMINE; PHOSPHOLIPASE D; TRPV1 PROTEIN, RAT; VANILLOID RECEPTOR;

ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC CONSTRICTION INJURY; CONTROLLED STUDY; DEGRADATION; ENZYME DEGRADATION; HYPERALGESIA; LUMBAR SPINAL CORD; MALE; METABOLISM; NEUROPATHIC PAIN; NOCICEPTION; NONHUMAN; PAIN RECEPTOR; PATHOGENESIS; PHENOTYPE; PROTEIN EXPRESSION; RAT; SPINAL GANGLION; SYNTHESIS; UPREGULATION; ANIMAL; CHRONIC DISEASE; COMPLICATION; GENE EXPRESSION REGULATION; GENETICS; INJURIES; LIGATION; LUMBAR VERTEBRA; NEURALGIA; PAIN THRESHOLD; PATHOLOGY; PATHOPHYSIOLOGY; SCIATIC NERVE; STENOSIS, OCCLUSION AND OBSTRUCTION; WISTAR RAT;

ANIMALIA;

ANIMALS; ARACHIDONIC ACIDS; CHRONIC DISEASE; CONSTRICTION, PATHOLOGIC; ENDOCANNABINOIDS; GANGLIA, SPINAL; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HYPERALGESIA; LIGATION; LUMBAR VERTEBRAE; MALE; NEURALGIA; PAIN THRESHOLD; PHOSPHATIDYLETHANOLAMINES; PHOSPHOLIPASE D; POLYUNSATURATED ALKAMIDES; RATS, WISTAR; RECEPTOR, CANNABINOID, CB2; RNA, MESSENGER; SCIATIC NERVE; TRPV CATION CHANNELS; UP-REGULATION;

EID: 84922489920     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/686908     Document Type: Article

References (69)

1. Z. Ali, S. N. Raja, U. Wesselmann, P. N. Fuchs, R. A. Meyer, and J. N. Campbell, "Intradermal injection of norepinephrine evokes pain in patients with sympathetically maintained pain, " Pain, vol. 88, no. 2, pp. 161-168, 2000.
2. M. A. Rogawski and W. Loscher, "The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions, " Nature Medicine, vol. 10, no. 7, pp. 685-692, 2004.
3. D. S. Goldberg and S. J. McGee, "Pain as a global public health priority, " BMC Public Health, vol. 11, no. 1, article 770, 2011.
4. B. Costa, M. Colleoni, S. Conti, et al., "Repeated treatment with the synthetic cannabinoid WIN 55, 212-2 reduces both hyperalgesia and production of pronociceptive mediators in a ratmodel of neuropathic pain, " British Journal of Pharmacology, vol. 141, no. 1, pp. 4-8, 2004.
5. B. Costa, A. E. Trovato, F. Comelli, G. Giagnoni, and M. Colleoni, "The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain, " European Journal of Pharmacology, vol. 556, no. 1-3, pp. 75-83, 2007.
6. E. Palazzo, V. de Novellis, S. Petrosino, et al., "Neuropathic pain and the endocannabinoid system in the dorsal raphe: pharmacological treatment and interactions with the serotonergic system, " European Journal of Neuroscience, vol. 24, no. 7, pp. 2011-2020, 2006.
7. M. M. Ibrahim, H. Deng, A. Zvonok, et al., "Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS, " Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 18, pp. 10529-10533, 2003.
8. J. Guindon and P. Beaulieu, "Antihyperalgesic effects of local injections of anand amide, ibuprof en, rof ecoxib and their combinations in a model of neuropathic pain, " Neuropharmacology, vol. 50, no. 7, pp. 814-823, 2006.
9. A. Jayamanne, R. Greenwood, V. A. Mitchell, S. Aslan, D. Piomelli, and C. W. Vaughan, "Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models, " British Journal of Pharmacology, vol. 147, no. 3, pp. 281-288, 2006.
10. A. Fox, A. Kesingland, C. Gentry, et al., "The role of central and peripheral Cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain, " Pain, vol. 92, no. 1-2, pp. 91-100, 2001.
11. S. Petrosino and V. Di Marzo, "FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels, " Current Opinion in Investigational Drugs, vol. 11, no. 1, pp. 51-62, 2010.
12. S. G. Kinsey, J. Z. Long, S. T. ONeal, et al., "Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain, " Journal of Pharmacology and Experimental Therapeutics, vol. 330, no. 3, pp. 902-910, 2009.
13. K. Starowicz, W. Makuch, M. Osikowicz, et al., "Spinal anand amide produces analgesia in neuropathic rats: possible CB1-and TRPV1-mediated mechanisms, " Neuropharmacology, vol. 62, no. 4, pp. 1746-1755, 2012.
14. K. Starowicz and B. Przewlocka, "Modulation of neuropathicpain-related behaviour by the spinal endocannabinoid/endovanilloid system, " Philosophical Transactions of the Royal Society B: Biological Sciences, vol. 367, no. 1607, pp. 3286-3299, 2012.
15. V. DiMarzo and L. De Petrocellis, "Why do cannabinoid receptors have more than one endogenous ligand ?" Philosophical Transactions of the Royal Society B, vol. 367, no. 1607, pp. 3216-3228, 2012.
16. J. Sousa-Valente, A. Varga, K. Ananthan, A. Khajuria, and I. Nagy, "Anand amide in primary sensory neurons: too much of a good thing?" European Journal of Neuroscience, vol. 39, no. 3, pp. 409-418, 2014.
17. P. M. Zygmunt, J. Petersson, D. A. Andersson, et al., "Vanilloid receptors on sensory nerves mediate the vasodilator action of anand amide, " Nature, vol. 400, no. 6743, pp. 452-457, 1999.
18. P. Movahed, B. A. G. Jonsson, B. Birnir, et al., "Endogenous unsaturated C18 β-acylethanolamines are vanilloid receptor (TRPV1) agonists, " The Journal of Biological Chemistry, vol. 280, no. 46, pp. 38496-38504, 2005.
19. W. J. Martin, P. O. Coffin, E. Attias, M. Balinsky, K. Tsou, and J. M. Walker, "Anatomical basis for cannabinoid-induced antinociception as revealed by intracerebral microinjections, " Brain Research, vol. 822, no. 1-2, pp. 237-242, 1999.
20. J. M. Walker, S. M. Huang, N. M. Strangman, K. Tsou, and M. C. Sanudo-Pena, "Pain modulation by release of the endogenous cannabinoid anand amide, " Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 21, pp. 12198-12203, 1999.
21. A. G. Hohmann, R. L. Suplita, N. M. Bolton, et al., "An endocannabinoid mechanism for stress-induced analgesia, " Nature, vol. 435, no. 7045, pp. 1108-1112, 2005.
22. P. Bishay, H. Schmidt, C. Marian, et al., "R-flurbiprof en reduces neuropathic pain in rodents by restoring endogenous cannabinoids, " PLoS ONE, vol. 5, no. 5, Article ID e10628, 2010.
23. P. Bishay, A. Haussler, H.-Y. Lim, et al., "Anand amide deficiency and heightened neuropathic pain in aged mice, " Neuropharmacology, vol. 71, pp. 204-215, 2013.
24. S. Petrosino, E. Palazzo, V. de Novellis, et al., "Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats, " Neuropharmacology, vol. 52, no. 2, pp. 415-422, 2007.
25. M. D. Jhaveri, D. Richardson, D. A. Kendall, D. A. Barrett, and V. Chapman, "Analgesic effects of fatty acid amide hydrolase inhibition in a rat model of neuropathic pain, " The Journal of Neuroscience, vol. 26, no. 51, pp. 13318-13327, 2006.
26. M. Van Der Stelt, M. Trevisani, V. Vellani, et al., "Anand amide acts as an intracellular messenger amplifying Ca2+ influx via TRPV1 channels, " The EMBO Journal, vol. 24, no. 17, pp. 3026-3037, 2005.
27. G. G. Muccioli, "Endocannabinoid biosynthesis and inactivation, from simple to complex, " Drug Discovery Today, vol. 15, no. 11-12, pp. 474-483, 2010.
28. V. Vellani, S. Petrosino, L. de Petrocellis, et al., "Functional lipidomics. Calcium-independent activation of endocannabinoid/endovanilloid lipid signalling in sensory neurons by protein kinases C and A and thrombin, " Neuropharmacology, vol. 55, no. 8, pp. 1274-1279, 2008.
29. J. Liu, L. Wang, J. Harvey-White, et al., "A biosynthetic pathway for anand amide, " Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 36, pp. 13345-13350, 2006.
30. J. Liu, L. Wang, J. Harvey-White, et al., "Multiple pathways involved in the biosynthesis of anand amide, " Neuropharmacology, vol. 54, no. 1, pp. 1-7, 2008.
31. Y. Sun, K. Tsuboi, Y. Okamoto, et al., "Biosynthesis of anand amide and N-palmitoylethanolamine by sequential actions of phospholipase A2 and lysophospholipase D, " Biochemical Journal, vol. 380, part 3, pp. 749-756, 2004.
32. M. Maccarrone, M. Attina, M. Bari, A. Cartoni, C. Ledent, and A. Finazzi-Agro, "Anand amide degradation and Nacylethanolamines level in wild-type and CB1 cannabinoid receptor knockout mice of different ages, " Journal of Neurochemistry, vol. 78, no. 2, pp. 339-348, 2001.
33. K. Starowicz, W. Makuch, M. Korostynski, et al., "Full inhibition of spinal FAAH leads to TRPV1-mediated analgesic effects in neuropathic rats and possible lipoxygenase-mediated remodeling of anand amide metabolism, " PLoS ONE, vol. 8, no. 4, Article ID e60040, 2013.
34. C. A. Rouzer and L. J. Marnett, "Non-redundant functions of cyclooxygenases: oxygenation of endocannabinoids, " The Journal of Biological Chemistry, vol. 283, no. 13, pp. 8065-8069, 2008.
35. W. B. Veldhuis, M. van der Stelt, M. W. Wadman, et al., "Neuroprotection by the endogenous cannabinoid anand amide and arvanil against in vivo excitotoxicity in the rat: role of vanilloid receptors and lipoxygenases, " Journal of Neuroscience, vol. 23, no. 10, pp. 4127-4133, 2003.
36. E. J. Rahn and A. G. Hohmann, "Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside, " Neurotherapeutics, vol. 6, no. 4, pp. 713-737, 2009.
37. D. R. Sagar, S. Kelly, P. J. Millns, C. T. OShaughnessey, D. A. Kendall, and V. Chapman, "Inhibitory effects of CB1 and CB2 receptor agonists on responses of DRGneurons and dorsal horn neurons in neuropathic rats, " European Journal of Neuroscience, vol. 22, no. 2, pp. 371-379, 2005.
38. L. Guasti, D. Richardson, M. Jhaveri, et al., "Minocycline treatment inhibits microglial activation and alters spinal levels of endocannabinoids in a rat model of neuropathic pain, " Molecular Pain, vol. 5, article 35, 2009.
39. I. A. Khasabova, S. G. Khasabov, C. Harding-Rose, et al., "A decrease in anand amide signaling contributes to the maintenance of cutaneous mechanical hyperalgesia in amodel of bone cancer pain, " The Journal of Neuroscience, vol. 28, no. 44, pp. 11141-11152, 2008.
40. B. N. Okine, L. M. Norris, S. Woodhams, et al., "Lack of effect of chronic pre-treatment with the FAAH inhibitor URB597 on inflammatory pain behaviour: evidence for plastic changes in the endocannabinoid system, " British Journal of Pharmacology, vol. 167, no. 3, pp. 627-640, 2012.
41. D. Leung, A. Saghatelian, G. M. Simon, and B. F. Cravatt, "Inactivation of N-Acyl phosphatidylethanolamine phospholipase D reveals multiple mechanisms for the biosynthesis of endocannabinoids, " Biochemistry, vol. 45, no. 15, pp. 4720-4726, 2006.
42. G. M. Simon and B. F. Cravatt, "Characterization of mice lacking cand idate β-acyl ethanolamine biosynthetic enzymes provides evidence for multiple pathways that contribute to endocannabinoid production in vivo, " Molecular BioSystems, vol. 6, no. 8, pp. 1411-1418, 2010.
43. A. Varga, A. Jenes, T. H. Marczylo, et al., "Anand amide produced by Ca(2+)-insensitive enzymes induces excitation in primary sensory neurons, " Pflugers Archiv, vol. 466, no. 7, pp. 1421-1435, 2013.
44. K. R. Kozak, J. J. Prusakiewicz, and L. J. Marnett, "Oxidative metabolism of endocannabinoids by COX-2, " Current Pharmaceutical Design, vol. 10, no. 6, pp. 659-667, 2004.
45. M. D. Jhaveri, D. Richardson, I. Robinson, et al., "Inhibition of fatty acid amide hydrolase and cyclooxygenase-2 increases levels of endocannabinoid related molecules and produces analgesia via peroxisome proliferator-activated receptor-alpha in a model of inflammatory pain, " Neuropharmacology, vol. 55, no. 1, pp. 85-93, 2008.
46. B. Costa, F. Comelli, I. Bettoni, M. Colleoni, and G. Giagnoni, "The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB1, TRPV1 and PPAR receptors and neurotrophic factors, " Pain, vol. 139, no. 3, pp. 541-550, 2008.
47. S. Kelly, R. J. Chapman, S. Woodhams, et al., "Increased function of pronociceptive TRPV1 at the level of the joint in a rat model of osteoarthritis pain, " Annals of the Rheumatic Diseases, 2013.
48. M. Yu, D. Ives, and C. S. Ramesha, "Synthesis of prostagLandin E2 ethanolamide from anand amide by cyclooxygenase-2, " The Journal of Biological Chemistry, vol. 272, no. 34, pp. 21181-21186, 1997.
49. D. K. Nomura, B. E. Morrison, J. L. Blankman, et al., "Endocannabinoid hydrolysis generates brain prostagLandins that promote neuroinflammation, " Science, vol. 334, no. 6057, pp. 809-813, 2011.
50. A. Ligresti, J. Martos, J. Wang, et al., "Prostamide F(2) β receptor antagonism combined with inhibition of FAAH may block the pro-inflammatory mediators formed following selective FAAH inhibition, " British Journal of Pharmacology, vol. 171, no. 6, pp. 1408-1419, 2014.
51. M. van der Stelt, J. A. van Kuik, M. Bari, et al., "Oxygenated metabolites of anand amide and 2-arachidonoylglycerol: conformational analysis and interaction with cannabinoid receptors, membrane transporter, and fatty acid amide hydrolase, " Journal of Medicinal Chemistry, vol. 45, no. 17, pp. 3709-3720, 2002.
52. R. G. Pertwee, "Cannabinoid receptors and pain, " Progress in Neurobiology, vol. 63, no. 5, pp. 569-611, 2001.
53. D. Bridges, K. Ahmad, and A. S. C. Rice, "Thesynthetic cannabinoid WIN55, 212-2 attenuates hyperalgesia and allodynia in a ratmodel of neuropathic pain, " British Journal of Pharmacology, vol. 133, no. 4, pp. 586-594, 2001.
54. A. F. Paszcuk, R. C. Dutra, K. A. B. S. da Silva, N. L. M. Quintao, M. M. Campos, and J. B. Calixto, "Cannabinoid agonists inhibit neuropathic pain induced by brachial plexus avulsion in mice by affecting glial cells and MAP kinases, " PLoS ONE, vol. 6, no. 9, Article ID e24034, 2011.
55. S. Furuse, T. Kawamata, J. Yamamoto, et al., "Reduction of bone cancer pain by activation of spinal cannabinoid receptor 1 and its expression in the superficial dorsal horn of the spinal cord in amurinemodel of bone cancer pain, " Anesthesiology, vol. 111, no. 1, pp. 173-186, 2009.
56. J. Guindon, Y. Lai, S. M. Takacs, H. B. Bradshaw, and A. G. Hohmann, "Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following cisplatin treatment, " Pharmacological Research, vol. 67, no. 1, pp. 94-109, 2013.
57. N. Agarwal, P. Pacher, I. Tegeder, et al., "Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors, " Nature Neuroscience, vol. 10, no. 7, pp. 870-879, 2007.
58. J. Zhang, C. HOffert, H. K. Vu, T. Groblewski, S. Ahmad, and D. ODonnell, "Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models, " European Journal of Neuroscience, vol. 17, no. 12, pp. 2750-2754, 2003.
59. I. Racz, X. Nadal, J. Alferink, et al., "Crucial role of CB2 cannabinoid receptor in the regulation of central immune responses during neuropathic pain, " Journal of Neuroscience, vol. 28, no. 46, pp. 12125-12135, 2008.
60. M. Beltramo, N. Bernardini, R. Bertorelli, et al., "CB2 receptormediated antihyperalgesia: possible direct involvement of neural mechanisms, " European Journal of Neuroscience, vol. 23, no. 6, pp. 1530-1538, 2006.
61. A. Romero-Sandoval, N. Nutile-Mcmenemy, and J. A. Deleo, "Spinal microglial and perivascular cell cannabinoid receptor type 2 activation reduces behavioral hypersensitivity without tolerance after peripheral nerve injury, " Anesthesiology, vol. 108, no. 4, pp. 722-734, 2008.
62. E. J. Rahn, A. M. Zvonok, G. A. Thakur, A. D. Khanolkar, A. Makriyannis, and A. G. Hohmann, "Selective activation of cannabinoid CB2 receptors suppresses neuropathic nociception induced by treatment with the chemotherapeutic agent paclitaxel in rats, " The Journal of Pharmacology and Experimental Therapeutics, vol. 327, no. 2, pp. 584-591, 2008.
63. E. J. Rahn, A. Makriyannis, and A. G. Hohmann, "Activation of cannabinoid CB 1 and CB 2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats, " The British Journal of Pharmacology, vol. 152, no. 5, pp. 765-777, 2007.
64. Z. Winter, A. Buhala, F. Otvos, et al., "Functionally important amino acid residues in the transient receptor potential vanilloid (TRPV1) ion channel-an overview of the current mutational data, " Molecular Pain, vol. 9, no. 1, article 30, 2013.
65. M. Zimmermann, "Ethical guidelines for investigations of experimental pain in conscious animals, " Pain, vol. 16, no. 2, pp. 109-110, 1983.
66. M. Osikowicz, J. Mika, W. Makuch, and B. Przewlocka, "Glutamate receptor ligands attenuate allodynia and hyperalgesia and potentiate morphine effects in a mouse model of neuropathic pain, " Pain, vol. 139, no. 1, pp. 117-126, 2008.
67. S. J. R. Elmes, M. D. Jhaveri, D. Smart, D. A. Kendall, and V. Chapman, "Cannabinoid CB2 receptor activation inhibits mechanically evoked responses of wide dynamic range dorsal horn neurons in naive rats and in rat models of inflammatory and neuropathic pain, " European Journal of Neuroscience, vol. 20, no. 9, pp. 2311-2320, 2004.
68. G. J. Bennett and Y. K. Xie, "A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man, " Pain, vol. 33, no. 1, pp. 87-107, 1988.
69. P. Chomczynski and N. Sacchi, "Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chlorof orm extraction, " Analytical Biochemistry, vol. 162, no. 1, pp. 156-159, 1987.